Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Scholar Rock (NASDAQ: SRRK) has granted inducement equity awards to twelve new employees, totaling 208,800 shares of common stock. The awards consist of 119,312 shares as stock options with an exercise price of $45.48 and 89,488 shares as restricted stock units. The stock options will vest 25% after one year, with the remaining 75% vesting in 12 quarterly installments. The restricted stock units will vest in four equal annual installments. These grants were made under the Company's 2022 Inducement Equity Plan, specifically designed for new hires as per Nasdaq Listing Rule 5635(c)(4).
Scholar Rock (NASDAQ: SRRK) ha concesso premi azionari di incentivo a dodici nuovi dipendenti, per un totale di 208.800 azioni ordinarie. I premi consistono in 119.312 azioni come opzioni su azioni con un prezzo di esercizio di 45,48 dollari e 89.488 azioni come unità azionarie vincolate. Le opzioni su azioni matureranno il 25% dopo un anno, con il restante 75% che maturerà in 12 rate trimestrali. Le unità azionarie vincolate matureranno in quattro rate annuali uguali. Questi premi sono stati concessi nell'ambito del Piano 2022 di Incentivazione Azionaria della Società, appositamente progettato per i nuovi assunti secondo la Regola di Quotazione Nasdaq 5635(c)(4).
Scholar Rock (NASDAQ: SRRK) ha otorgado premios de acciones por inducción a doce nuevos empleados, totalizando 208,800 acciones ordinarias. Los premios consisten en 119,312 acciones como opciones sobre acciones con un precio de ejercicio de $45.48 y 89,488 acciones como unidades de acciones restringidas. Las opciones sobre acciones se consolidarán en un 25% después de un año, y el 75% restante se consolidará en 12 cuotas trimestrales. Las unidades de acciones restringidas se consolidarán en cuatro cuotas anuales iguales. Estos premios se otorgaron bajo el Plan de Inducción de Acciones 2022 de la Compañía, diseñado específicamente para nuevos empleados según la Regla de Cotización Nasdaq 5635(c)(4).
스콜라 록 (NASDAQ: SRRK)는 12명의 신규 직원에게 유도 주식 보상을 제공하여 총 208,800주의 보통주를 부여했습니다. 이 보상은 119,312주의 주식 옵션과 89,488주의 제한 주식 단위로 구성되어 있습니다. 주식 옵션의 25%는 1년 후에 확정되며, 나머지 75%는 12회의 분기별 분할로 확정됩니다. 제한 주식 단위는 4회의 동등한 연간 분할로 확정됩니다. 이 보상은 Nasdaq 상장 규칙 5635(c)(4)에 따라 신규 채용을 위해 특별히 설계된 회사의 2022 유도 주식 계획에 따라 이루어졌습니다.
Scholar Rock (NASDAQ: SRRK) a accordé des attributions d'actions incitatives à douze nouveaux employés, totalisant 208 800 actions ordinaires. Les attributions consistent en 119 312 actions sous forme d'options d'actions avec un prix d'exercice de 45,48 $ et 89 488 actions sous forme d'unités d'actions restreintes. Les options d'actions deviendront acquises à hauteur de 25 % après un an, le 75 % restant étant acquis en 12 versements trimestriels. Les unités d'actions restreintes deviendront acquises en quatre versements annuels égaux. Ces attributions ont été effectuées dans le cadre du Plan d'Attribution d'Actions Incitatives 2022 de la Société, spécifiquement conçu pour les nouvelles recrues conformément à la règle de cotation Nasdaq 5635(c)(4).
Scholar Rock (NASDAQ: SRRK) hat zwölf neuen Mitarbeitern Anreizaktien zugewiesen, insgesamt 208.800 Stammaktien. Die Zuwendungen bestehen aus 119.312 Aktien in Form von Aktienoptionen mit einem Ausübungspreis von 45,48 USD und 89.488 Aktien in Form von eingeschränkten Aktieneinheiten. Die Aktienoptionen werden nach einem Jahr zu 25% fällig, während die verbleibenden 75% in 12 vierteljährlichen Raten fällig werden. Die eingeschränkten Aktieneinheiten werden in vier gleichen jährlichen Raten fällig. Diese Zuwendungen wurden im Rahmen des Unternehmensplans für Anreizaktien 2022 gewährt, der speziell für neueinstellungen gemäß der Nasdaq-Listing-Regel 5635(c)(4) konzipiert wurde.
- Successful attraction of 12 new employees indicating company growth
- Stock options granted at market price ($45.48) aligning employee interests with shareholders
- Potential dilution of existing shareholders due to 208,800 new shares issuance
The awards are subject to all terms and conditions and other provisions set forth in the Company’s 2022 Inducement Equity Plan (the “Plan”) and the award agreements thereunder.
The Plan, initially adopted by the Company’s board of directors on June 16, 2022, and as amended from time to time, is used exclusively for the grant of equity awards to individuals who were not previously employees of Scholar Rock, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with Scholar Rock, pursuant to Nasdaq Listing Rule 5635(c)(4).
The inducement stock options have an exercise price of
About Scholar Rock
Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade, Scholar Rock has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role.
Scholar Rock is the only company to show clinical proof-of-concept for a muscle-targeted treatment in spinal muscular atrophy (SMA). This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about our approach at ScholarRock.com and follow @ScholarRock and on LinkedIn.
Scholar Rock® is a registered trademark of Scholar Rock, Inc.
Availability of Other Information About Scholar Rock
Investors and others should note that we communicate with our investors and the public using our company website www.scholarrock.com, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on Twitter and LinkedIn. The information that we post on our website or on Twitter or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241213934828/en/
Scholar Rock:
Investors
Rushmie Nofsinger
Scholar Rock
rnofsinger@scholarrock.com
ir@scholarrock.com
857-259-5573
Media
Molly MacLeod
Scholar Rock
mmacleod@scholarrock.com
media@scholarrock.com
802-579-5995
Source: Scholar Rock
FAQ
How many shares did Scholar Rock (SRRK) grant in its December 2024 inducement awards?
What is the exercise price for SRRK's December 2024 inducement stock options?
What is the vesting schedule for SRRK's December 2024 inducement stock options?
How do the restricted stock units vest in SRRK's December 2024 inducement grants?
